GSK plc announced that Japan’s Ministry of Health, Labour and Welfare, or MHLW, has approved Arexvy for the prevention of RSV, or respiratory syncytial virus, disease for adults 60 years of age and above. “This is the first time an RSV vaccine for older adults has been approved in Japan,” the company stated. Tony Wood, Chief Scientific Officer at GSK, said: “Arexvy is Japan’s first approved RSV older adult vaccine, and is a major advance for public health with the potential to help protect around 43.5 million Japanese people aged 60 and older. Following key approvals in the US, EU, UK and Canada earlier this year, today’s authorisation reinforces GSK’s industry-leading vaccine portfolio.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GSK:
- Cantor Fitzgerald biotech analysts to hold an analyst/industry conference call
- Procter & Gamble Stock (NYSE:PG): Quality Comes at a Hefty Price
- Citi sees Incyte’s Jakafi remaining dominant after GSK approval
- GSK announces European Commission authorized ViiV Healthcare’s Apretude
- GSK price target raised to 1,575 GBp from 1,450 GBp at Barclays